ALLMedicine™ Hypertriglyceridemia Center

Oct 23rd, 2021 - Leptin replacement with metreleptin improves glycemia and hypertriglyceridemia in severely hypoleptinemic patients with Generalized Lipodystrophy (GLD), but its effects are variable in partially leptin-deficient patients with Partial Lipodystrophy...

Oct 22nd, 2021 - Two cohorts are being studied based on leptin levels. Cohort A is composed of patients with baseline leptin <8.0 ng/mL and Cohort B is composed of patients with baseline leptin 8.0 to ≤20.0 ng/mL The primary objectives will be evaluated for patien...

Oct 20th, 2021 - This study will build upon a previous finding that showed a triglyceride lowering effect of prescription omega-3 in combined therapy with statins. The proposed study will use a simple change from baseline design on 15 subjects who are hypertriglyc...

Oct 16th, 2021 - Angiopoietin-like protein 3 (ANGPTL3) is a key physiological regulator of plasma lipid and lipoprotein metabolism that involves the control of enzymes, lipoprotein and endothelial lipases. Inhibition of ANGPTL3 offers a new approach for correcting...

Oct 12th, 2021 - To evaluate the prevalence and prognostic value of metabolic syndrome (MetS) in patients admitted for coronavirus disease 2019 (COVID-19). In this monocentric cohort retrospective study, we consecutively included all adult patients admitted to COV...

Aug 2nd, 2021 - 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.|2021|Virani SS,Morris PB,Agarwa...

Oct 22nd, 2021 - Two cohorts are being studied based on leptin levels. Cohort A is composed of patients with baseline leptin <8.0 ng/mL and Cohort B is composed of patients with baseline leptin 8.0 to ≤20.0 ng/mL The primary objectives will be evaluated for patien...

Oct 20th, 2021 - This study will build upon a previous finding that showed a triglyceride lowering effect of prescription omega-3 in combined therapy with statins. The proposed study will use a simple change from baseline design on 15 subjects who are hypertriglyc...

Sep 24th, 2021 - Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from simple reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH). The mechanisms behind why some subjects progress from NAFLD to NASH are not clear and ...

Aug 30th, 2021 - Elevated cholesterol, including triglyceride levels, can lead to the development of cardiovascular disease in adulthood. A diet that is rich in omega-3 fatty acids (O3FA) can improve triglyceride levels in a way that is safe and does not require m...

Aug 19th, 2021 - Type I hyperlipoproteinemia is a rare, autosomal recessive metabolic disorder characterized by extreme hypertriglyceridemia due to a deficiency in lipoprotein lipase or related proteins. Treatment of these patients is challenging as triglyceride-l...

Jul 29th, 2021 - A new decision pathway for the management of hypertriglyceridemia, prompted by a large and growing body of evidence that elevated triglycerides to a targetable risk factor for atherosclerotic cardiovascular disease (ASCVD), has been issued by the ...

Apr 2nd, 2021 - Transcript: Susan F. Slovin, MD, PhD: Going into a chemical-induced menopause is not great for a lot of men. It’s interesting when we discuss adverse effects to really keep in mind that while there is a huge number of adverse effects that occu...

Feb 25th, 2021 - This patient had hand and foot psoriasis with the classic thick scale and erythema on his palms and soles. Additionally, in the area of the sole toward the heel, he had hyperpigmented macules called mahogany spots that are another hallmark of psor.

Feb 23rd, 2021 - The interleukin (IL)-1 receptor antagonist anakinra (Kineret) was not superior to triamcinolone for relieving gout flares, but had similar effects for pain reduction as the glucocorticoid, a randomized phase II study found. The mean change from ba...

Dec 29th, 2020 - The filing of a new drug application (NDA) has been initiated with the FDA for surufatinib for the treatment of patients with pancreatic and non-pancreatic neuroendocrine tumors.1 Hutchison China MediTech Limited (Chi-Med), the developer of suruf...